Chemical Namesebelipase alfa
Dosage FormInjection (intravenous; 20 mg/10 mL)
Drug ClassEnzymes
SystemDigestive, Cardiovascular, Blood
CompanyAlexion Pharmaceuticals Inc.
Approval Year2015


  • To treat patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.
Last updated on 10/30/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Kanuma (sebelipase alfa) Prescribing Information 2015Alexion Pharmaceuticals Inc., New Haven, CT